JP2022533215A5 - - Google Patents

Info

Publication number
JP2022533215A5
JP2022533215A5 JP2021568944A JP2021568944A JP2022533215A5 JP 2022533215 A5 JP2022533215 A5 JP 2022533215A5 JP 2021568944 A JP2021568944 A JP 2021568944A JP 2021568944 A JP2021568944 A JP 2021568944A JP 2022533215 A5 JP2022533215 A5 JP 2022533215A5
Authority
JP
Japan
Prior art keywords
indicates
bond
nhc
independently selected
spacer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021568944A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022533215A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/033648 external-priority patent/WO2020236841A2/en
Publication of JP2022533215A publication Critical patent/JP2022533215A/ja
Publication of JP2022533215A5 publication Critical patent/JP2022533215A5/ja
Priority to JP2025144373A priority Critical patent/JP2026000940A/ja
Pending legal-status Critical Current

Links

JP2021568944A 2019-05-20 2020-05-19 親水性基を含むリンカーを有する抗体薬剤コンジュゲート Pending JP2022533215A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025144373A JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962850094P 2019-05-20 2019-05-20
US62/850,094 2019-05-20
PCT/US2020/033648 WO2020236841A2 (en) 2019-05-20 2020-05-19 Antibody drug conjugates having linkers comprising hydrophilic groups

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025144373A Division JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Publications (2)

Publication Number Publication Date
JP2022533215A JP2022533215A (ja) 2022-07-21
JP2022533215A5 true JP2022533215A5 (cg-RX-API-DMAC7.html) 2023-05-26

Family

ID=71070004

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021568944A Pending JP2022533215A (ja) 2019-05-20 2020-05-19 親水性基を含むリンカーを有する抗体薬剤コンジュゲート
JP2025144373A Pending JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025144373A Pending JP2026000940A (ja) 2019-05-20 2025-09-01 親水性基を含むリンカーを有する抗体薬剤コンジュゲート

Country Status (9)

Country Link
US (1) US20230091510A1 (cg-RX-API-DMAC7.html)
EP (1) EP3972650A2 (cg-RX-API-DMAC7.html)
JP (2) JP2022533215A (cg-RX-API-DMAC7.html)
KR (1) KR20220010527A (cg-RX-API-DMAC7.html)
CN (3) CN119613486A (cg-RX-API-DMAC7.html)
AU (2) AU2020279731B2 (cg-RX-API-DMAC7.html)
CA (1) CA3140063A1 (cg-RX-API-DMAC7.html)
IL (1) IL287596A (cg-RX-API-DMAC7.html)
WO (1) WO2020236841A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240238440A1 (en) * 2021-04-29 2024-07-18 Hyslink Therapeutics Preparation method for and application of antibody conjugated drug
KR20240016287A (ko) 2021-06-01 2024-02-06 아지노모토 가부시키가이샤 항체 및 기능성 물질의 콘쥬게이트 또는 이의 염, 및 이의 제조에 사용되는 화합물 또는 이의 염
EP4349371A4 (en) * 2021-06-02 2025-06-25 Bio-Thera Solutions, Ltd. DRUG CONJUGATE AND USE THEREOF
CN117500528A (zh) * 2021-06-18 2024-02-02 北京海步医药科技有限公司 连接子及其缀合物
EP4509141A4 (en) * 2022-04-12 2026-08-19 Bio Thera Solutions Ltd TREATMENT METHOD FOR A HER2-POSITIVE SOLID TUMOR
KR20250011947A (ko) * 2022-05-20 2025-01-22 노파르티스 아게 항체 약물 콘쥬게이트
CA3266848A1 (en) * 2022-10-19 2024-04-25 Multitude Therapeutics Inc. Antibodies, antibody-drug conjugates, preparations and uses thereof
CN116036303B (zh) * 2023-01-10 2025-06-24 金麦安博生物制药(苏州)有限公司 一种抗体-药物偶联物及其制备方法和应用
JP2026504840A (ja) * 2023-01-11 2026-02-10 ジェンマブ エー/エス リンカー、薬物リンカー、およびそれらの複合体、ならびにそれらを使用する方法
CN118852442A (zh) 2023-04-26 2024-10-29 上海麦科思生物医药有限公司 抗ptk7抗体及其用途
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
WO2025228305A1 (zh) * 2024-04-28 2025-11-06 中国科学院上海药物研究所 一种蛋白降解剂缀合物及其偶联物
KR20250164033A (ko) * 2024-05-14 2025-11-24 주식회사 지놈앤컴퍼니 항-bcam 항체 및 이의 컨쥬게이트
WO2025255381A1 (en) * 2024-06-05 2025-12-11 Sigma-Aldrich Co. Llc Chito-oligosaccharide drug constructs
WO2026046186A1 (en) * 2024-08-27 2026-03-05 Suzhou Bioreinno Biotechnology Limited Company Linkers, linker conjugates and conjugate compounds thereof
WO2026105061A1 (en) 2024-11-15 2026-05-21 Pheon Therapeutics Ltd Antibody-drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 感染性の呼吸性疾患の治療方法
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
AU4116793A (en) 1992-04-24 1993-11-29 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5985320A (en) 1996-03-04 1999-11-16 The Penn State Research Foundation Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ,インコーポレイティド 人工抗体ポリペプチド
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
ES2198922T3 (es) 1998-06-24 2004-02-01 Advanced Inhalation Research, Inc. Particulas porosas grandes emitadas por un inhalador.
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
PL213948B1 (pl) 2001-10-25 2013-05-31 Genentech Inc Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
AU2013350802B2 (en) 2012-11-30 2016-07-14 Novartis Ag Methods for making conjugates from disulfide-containing proteins
KR20210132742A (ko) * 2012-12-21 2021-11-04 알트루바이오 인코퍼레이티드 친수성 자기-희생 링커 및 그것의 포합체
EA201591465A1 (ru) 2013-02-08 2015-12-30 АйАрЭм ЭлЭлСи Специфичные участки для модификации антител для получения иммуноконъюгатов
PT3057585T (pt) * 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
EP3125943B1 (en) * 2014-04-04 2026-04-22 Merck Sharp & Dohme LLC Phosphate based linkers for intracellular delivery of drug conjugates
KR20170020868A (ko) * 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
WO2015196089A1 (en) * 2014-06-20 2015-12-23 Bioalliance C.V. Anti-cd22 antibody-drug conjugates and methods of using thereof
RU2017123942A (ru) * 2014-12-09 2019-01-11 Эббви Инк. Ингибирующие bcl-xl соединения, обладающие низкой клеточной проницаемостью, и коньюгаты антитело-лекарственное средство, включающие их
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
CN116059201A (zh) * 2016-06-08 2023-05-05 艾伯维公司 抗egfr抗体药物偶联物
CN108066772B (zh) * 2016-11-14 2021-07-13 中国科学院上海药物研究所 靶向tacstd2的抗体与药物偶联体(adc)分子
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
US10646585B2 (en) * 2017-09-15 2020-05-12 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and ligand-drug conjugates thereof
EP3700577A1 (en) * 2017-10-23 2020-09-02 Mablink Bioscience Ligand-drug-conjugate comprising a single molecular weight polysarcosine
CA3247730A1 (en) * 2017-11-07 2025-10-30 Regeneron Pharmaceuticals, Inc. Hydrophilic linkers for antibody drug conjugates

Similar Documents

Publication Publication Date Title
CN1056162C (zh) 聚胺化的配位体及其金属配合物
US7150882B2 (en) Enhanced circulation effector composition and method
JP2023512455A5 (cg-RX-API-DMAC7.html)
JP2023113639A (ja) ビス-オクタヒドロフェナントレンカルボキサミド及びそのタンパク質コンジュゲート
US20100160485A1 (en) Hydrolysis stable self-etching, self-priming adhesive
JP2022512643A5 (cg-RX-API-DMAC7.html)
AU2004201789A1 (en) Fc receptor modulators and uses thereof
RU98120057A (ru) Производные d-пролина
JP6051223B2 (ja) ペプチドの放出可能な結合のためのチロシンに基づくリンカー
JP2007535474A (ja) 複合補体カスケードインヒビター
WO2006088248A1 (ja) ポリオキシアルキレン誘導体
JP2003506491A5 (cg-RX-API-DMAC7.html)
FI78300B (fi) Foerfarande foer framstaellning av farmakologiskt verkande fosfatidylfoereningar.
JP2020183404A (ja) 第viii因子両性イオンポリマーコンジュゲート
JP2008528549A (ja) 構造的に充分に定義された分岐ポリマーと接合されたインスリン誘導体
JP2022512401A5 (cg-RX-API-DMAC7.html)
JP2024509282A5 (cg-RX-API-DMAC7.html)
JP2019507126A5 (cg-RX-API-DMAC7.html)
JP2024542021A5 (cg-RX-API-DMAC7.html)
EP0753004A1 (en) Antagonists of endothelin receptors
JP3274225B2 (ja) アミノ酸誘導体及びその用途
JP2025514282A5 (cg-RX-API-DMAC7.html)
KR20070010175A (ko) 온화한 가티올분해 조건하에서 방출될 수 있는 폴리머콘쥬게이트
RU2021137409A (ru) Конъюгаты антитело-лекарственное средство, содержащие линкеры, содержащие гидрофильные группы
RU2024138136A (ru) Конъюгаты антитела и лекарственного средства